Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 5/2016

01-05-2016 | Original Article

Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation

Authors: Fei Zhao, Jia Ming, Yan Zhou, Linjun Fan

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2016

Login to get access

Abstract

Purpose

Breast cancer is the most common type of cancer with high incidence in women. Currently, identifying new therapies that selectively inhibit tumor growth without damaging normal tissue are a major challenge of cancer research. One of the features of cancer cells is that they do not consume more oxygen even under normal oxygen circumstances but prefer to aerobic glycolysis through the enhanced catabolism of glucose and glutamine. In this study, we investigate the mechanisms of the radioresistance in breast cancer cells.

Methods

Human breast cancer cells MDA-MB-231 and MCF-7 were treated with radiation alone, Glut1 inhibitor alone or the combination of both to evaluate cell glucose metabolism and apoptosis. By the establishment of radioresistant cell line, we investigate the mechanisms of the combined treatments of radiation with Glut1 inhibitor in the radioresistant cells.

Results

The glucose metabolism and the expression of Glut1 are significantly stimulated by radiotherapy. We report the radioresistant breast cancer cells exhibit upregulated Glut1 expression and glucose metabolism. In addition, we observed overexpression of Glut1 renders breast cancer cells resistant to radiation and knocking down of Glut1 sensitizes breast cancer cells to radiation. We treated breast cancer cells with radiation and WZB117 which inhibits Glut1 expression and glucose metabolism and found the combination of WZB117 and radiation exhibits synergistically inhibitory effects on breast cancer cells. Finally, we demonstrate the inhibition of Glut1 re-sensitizes the radioresistant cancer cells to radiation.

Conclusions

This study reveals the roles of Glut1 in the radiosensitivity of human breast cancer. It will provide new mechanisms and strategies for the sensitization of cancer cells to radiotherapy through regulation of glucose metabolism.
Literature
1.
go back to reference Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ (2013) Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 4:117–132CrossRefPubMedPubMedCentral Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ (2013) Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 4:117–132CrossRefPubMedPubMedCentral
2.
go back to reference Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC (2014) Past, present, and future challenges in breast cancer treatment. J Clin Oncol 32:1979–1986CrossRefPubMed Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC (2014) Past, present, and future challenges in breast cancer treatment. J Clin Oncol 32:1979–1986CrossRefPubMed
3.
go back to reference Hassan MS, Ansari J, Spooner D, Hussain SA (2010) Chemotherapy for breast cancer. Oncol Rep 24:1121–1131CrossRefPubMed Hassan MS, Ansari J, Spooner D, Hussain SA (2010) Chemotherapy for breast cancer. Oncol Rep 24:1121–1131CrossRefPubMed
4.
go back to reference Delaney G, Jacob S, Featherstone C, Barton M (2005) The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104:1129–1137CrossRefPubMed Delaney G, Jacob S, Featherstone C, Barton M (2005) The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104:1129–1137CrossRefPubMed
5.
go back to reference Jameel JK, Rao VS, Cawkwell L, Drew PJ (2004) Radioresistance in carcinoma of the breast. Breast 13:452–460CrossRefPubMed Jameel JK, Rao VS, Cawkwell L, Drew PJ (2004) Radioresistance in carcinoma of the breast. Breast 13:452–460CrossRefPubMed
6.
go back to reference Huang EY, Chen YF, Chen YM, Lin IH, Wang CC, Su WH, Chuang PC, Yang KD (2012) A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis 3:e251CrossRefPubMedPubMedCentral Huang EY, Chen YF, Chen YM, Lin IH, Wang CC, Su WH, Chuang PC, Yang KD (2012) A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis 3:e251CrossRefPubMedPubMedCentral
7.
go back to reference Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, McKenna WG, Muschel RJ, Hiraoka M (2012) Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 3:783CrossRefPubMedPubMedCentral Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, McKenna WG, Muschel RJ, Hiraoka M (2012) Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 3:783CrossRefPubMedPubMedCentral
10.
go back to reference Bhatt AN, Chauhan A, Khanna S, Rai Y, Singh S, Soni R, Kalra N, Dwarakanath BS (2015) Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells. BMC Cancer 15:335CrossRefPubMedPubMedCentral Bhatt AN, Chauhan A, Khanna S, Rai Y, Singh S, Soni R, Kalra N, Dwarakanath BS (2015) Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells. BMC Cancer 15:335CrossRefPubMedPubMedCentral
11.
go back to reference Zhong J, Rajaram N, Brizel DM, Frees AE, Ramanujam N, Batinic-Haberle I, Dewhirst MW (2013) Radiation induces aerobic glycolysis through reactive oxygen species. Radiother Oncol 106:390–396CrossRefPubMedPubMedCentral Zhong J, Rajaram N, Brizel DM, Frees AE, Ramanujam N, Batinic-Haberle I, Dewhirst MW (2013) Radiation induces aerobic glycolysis through reactive oxygen species. Radiother Oncol 106:390–396CrossRefPubMedPubMedCentral
12.
go back to reference Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11:1672–1682CrossRefPubMed Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11:1672–1682CrossRefPubMed
13.
go back to reference Shibuya KI, Okada M, Suzuki S, Seino MI, Seino S, Takeda H, Kitanaka C (2015) Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget 6:651–661CrossRefPubMedPubMedCentral Shibuya KI, Okada M, Suzuki S, Seino MI, Seino S, Takeda H, Kitanaka C (2015) Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget 6:651–661CrossRefPubMedPubMedCentral
14.
go back to reference Liu W, Fang Y, Wang XT, Liu J, Dan X, Sun LL (2014) Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117. Asian Pac J Cancer Prev 15:7037–7041CrossRefPubMed Liu W, Fang Y, Wang XT, Liu J, Dan X, Sun LL (2014) Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117. Asian Pac J Cancer Prev 15:7037–7041CrossRefPubMed
15.
go back to reference Andrisse S, Koehler RM, Chen JE, Patel GD, Vallurupalli VR, Ratliff BA, Warren DE, Fisher JS (2014) Role of GLUT1 in regulation of reactive oxygen species. Redox Biol 2:764–771CrossRefPubMedPubMedCentral Andrisse S, Koehler RM, Chen JE, Patel GD, Vallurupalli VR, Ratliff BA, Warren DE, Fisher JS (2014) Role of GLUT1 in regulation of reactive oxygen species. Redox Biol 2:764–771CrossRefPubMedPubMedCentral
16.
go back to reference North PE, Waner M, Mizeracki A, Mihm MC Jr (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31:11–22CrossRefPubMed North PE, Waner M, Mizeracki A, Mihm MC Jr (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31:11–22CrossRefPubMed
17.
go back to reference Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR (2010) Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 202:371.e1-8 Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR (2010) Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 202:371.e1-8
18.
go back to reference Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG (2009) Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 30:2182–2192CrossRefPubMed Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG (2009) Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 30:2182–2192CrossRefPubMed
19.
go back to reference Bean JF, Qiu YY, Yu S, Clark S, Chu F, Madonna MB (2014) Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J Pediatr Surg 49:981–984CrossRefPubMed Bean JF, Qiu YY, Yu S, Clark S, Chu F, Madonna MB (2014) Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J Pediatr Surg 49:981–984CrossRefPubMed
20.
go back to reference Lomax ME, Folkes LK, O’Neill P (2013) Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (R Coll Radiol) 25:578–585CrossRef Lomax ME, Folkes LK, O’Neill P (2013) Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (R Coll Radiol) 25:578–585CrossRef
21.
go back to reference Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441CrossRefPubMed Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441CrossRefPubMed
22.
go back to reference Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W (2006) Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81:130–135CrossRefPubMed Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W (2006) Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81:130–135CrossRefPubMed
23.
go back to reference Shimura T, Noma N, Sano Y, Ochiai Y, Oikawa T, Fukumoto M, Kunugita N (2014) AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother Oncol 112:302–307CrossRefPubMed Shimura T, Noma N, Sano Y, Ochiai Y, Oikawa T, Fukumoto M, Kunugita N (2014) AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother Oncol 112:302–307CrossRefPubMed
Metadata
Title
Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation
Authors
Fei Zhao
Jia Ming
Yan Zhou
Linjun Fan
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3007-9

Other articles of this Issue 5/2016

Cancer Chemotherapy and Pharmacology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine